These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


222 related items for PubMed ID: 25631360

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 3. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
    Chan LJ, Feeney OM, Leong NJ, McLeod VM, Porter CJH, Williams CC, Kaminskas LM.
    Biomacromolecules; 2017 Sep 11; 18(9):2866-2875. PubMed ID: 28731677
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF.
    Curr Pharm Des; 2002 Sep 11; 8(24):2139-57. PubMed ID: 12369859
    [Abstract] [Full Text] [Related]

  • 7. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Sep 11; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 8. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
    Shahzadi SK, Qadir MA, Mahmood N, Ahmed M.
    Protein Pept Lett; 2020 Sep 11; 27(3):219-224. PubMed ID: 31612813
    [Abstract] [Full Text] [Related]

  • 9. PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
    Chan LJ, Bulitta JB, Ascher DB, Haynes JM, McLeod VM, Porter CJ, Williams CC, Kaminskas LM.
    Mol Pharm; 2015 Mar 02; 12(3):794-809. PubMed ID: 25644368
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sylatron: a pegylated interferon for use in melanoma.
    Patel JN, Walko CM.
    Ann Pharmacother; 2012 Jun 02; 46(6):830-8. PubMed ID: 22619474
    [Abstract] [Full Text] [Related]

  • 12. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.
    Clin Cancer Res; 2005 Sep 01; 11(17):6247-55. PubMed ID: 16144928
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.
    Regul Pept; 2012 Jan 10; 173(1-3):74-81. PubMed ID: 21985916
    [Abstract] [Full Text] [Related]

  • 14. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR.
    Semin Liver Dis; 2004 Jan 10; 24 Suppl 2():33-8. PubMed ID: 15346244
    [Abstract] [Full Text] [Related]

  • 15. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.
    Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJ.
    Mol Pharm; 2013 Aug 05; 10(8):2986-95. PubMed ID: 23750747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P.
    J Pharmacol Exp Ther; 2001 Jun 05; 297(3):1059-66. PubMed ID: 11356929
    [Abstract] [Full Text] [Related]

  • 18. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.
    Bioconjug Chem; 2006 Jun 05; 17(3):618-30. PubMed ID: 16704199
    [Abstract] [Full Text] [Related]

  • 19. In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy.
    Hu J, Wang G, Zhao W, Gao W.
    J Control Release; 2016 Sep 10; 237():71-7. PubMed ID: 27393654
    [Abstract] [Full Text] [Related]

  • 20. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
    Morçöl T, Weidner JM, Mehta A, Bell SJD, Block T.
    AAPS PharmSciTech; 2018 Jan 10; 19(1):395-412. PubMed ID: 28752471
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.